Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis

NCT03329885 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03329885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Terminated
Start date
November 2, 2017
Completion date
June 26, 2018
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, inflammatory bowel diseases, nonalcoholic steatohepatitis, psoriasis, rheumatoid arthritis